TRUNCATED ALK (ALKATI)-POSITIVE MALIGNANCY

Clinical trials for TRUNCATED ALK (ALKATI)-POSITIVE MALIGNANCY explained in plain language.

Never miss a new study

Get alerted when new TRUNCATED ALK (ALKATI)-POSITIVE MALIGNANCY trials appear

Sign up with your email to follow new studies for TRUNCATED ALK (ALKATI)-POSITIVE MALIGNANCY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New hope for rare bone cancer: targeted pills aim to shrink tumors

Disease control Not yet recruiting

This early-stage trial tests two targeted drugs, crizotinib and alectinib, in people with a rare bone cancer that has a specific genetic change (truncated ALK). The goal is to see if these drugs can shrink or control the cancer. The study enrolls about 10 adults whose cancer has …

Matched conditions: TRUNCATED ALK (ALKATI)-POSITIVE MALIGNANCY

Phase: PHASE1, PHASE2 • Sponsor: China Medical University Hospital • Aim: Disease control

Last updated May 05, 2026 11:54 UTC

TRUNCATED ALK (ALKATI)-POSITIVE MALIGNANCY

Get alerted when new TRUNCATED ALK (ALKATI)-POSITIVE MALIGNANCY trials appear

New hope for rare bone cancer: targeted pills aim to shrink tumors